Infectious Diseases in Critical Care Medicine

46. Ticehurst JR, Aird DZ, Dam LM, et al. Effective detection of toxigenic Clostridium difficile by a two-
    step algorithm including tests for antigen and cytotoxin. J Clin Microbiol 2006; 44(3):1145–1149.


47. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus
    vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; 2(8358):1043–1046.


48. Louie TJ, Peppe J, Watt CK, et al. Tolevamer, a novel nonantibiotic polymer, compared with
    vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.
    Clin Infect Dis 2006; 43(4):411–420.


49. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the
    treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis
    2007; 45(3):302–307.


50. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe
    Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002; 35(6):690–696.


51. Fekety R, Silva J, Kauffman C, et al. Treatment of antibiotic-associated Clostridium difficile colitis
    with oral vancomycin: comparison of two dosage regimens. Am J Med 1989; 86(1):15–19.


52. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy
    for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27(10):1169–1172.


53. Pelaez T, Alcala L, Alonso R, et al. Reassessment of Clostridium difficile susceptibility to
    metronidazole and vancomycin. Antimicrob Agents Chemother 2002; 46(6):1647–1650.


54. Bricker E, Garg R, Nelson R, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in
    adults. Cochrane Database Syst Rev 2005; (1):CD004610.


55. McPherson S, Rees CJ, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe,
    refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006; 49(5):640–645.


56. Lamontagne F, Labbe AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with
    fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg
    2007; 245(2):267–272.


57. Louie TJ, Gerson M, Grimard D. Results of a phase III trial comparing tolevamer, vancomycin and
    metronidazole in patients withClostridium difficile-associated diarrhea (CDAD), 2007.


58. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis
    2008; 46(suppl 1):S32–S42.


59. Wilcox MH, Fawley WN, Settle CD, et al. Recurrence of symptoms in Clostridium difficile infection—
    relapse or reinfection? J Hosp Infect 1998; 38(2):93–100.


60. Kelly CP, LaMont JT. Clostridium difficile—more difficult than ever. N Engl J Med 2008; 359(18):
    1932–1940.


61. Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial
    pathogens. Clin Infect Dis 2004; 39(2):219–226.


62. Kyne L, Kelly CP. Recurrent Clostridium difficile diarrhoea. Gut 2001; 49(1):152–153.


63. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the
    treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101(4):812–822.


64. Gerding DN, Muto CA, Owens RC Jr. Measures to control and prevent Clostridium difficile infection.
    Clin Infect Dis 2008; 46(suppl 1):S43–S49.

Clostridium difficileInfection in Critical Care 287